We are live on ! Find out more
VAM

Visium Asset Management Portfolio holdings

AUM $1.43B
1-Year Est. Return 3.58%
This Fund
S&P 500
This Quarter Est. Return
+14.5%
1 Year Est. Return
-3.58%
3 Year Est. Return
+100.3%
5 Year Est. Return
10 Year Est. Return
AUM
$6.78B
AUM Growth
-$305M
Cap. Flow
-$1.04B
Cap. Flow %
-15.36%
Top 10 Hldgs %
29.21%
Holding
1,363
New
346
Increased
312
Reduced
313
Closed
357

Top Buys

Rank Stock Value
1
PRGO icon
Perrigo
PRGO
+$251M
2
AGN
Allergan plc
AGN
+$209M
3
CI icon
Cigna
CI
+$106M
4
ESPR
Esperion Therapeutics
ESPR
+$77.7M
5
LH icon
Labcorp
LH
+$52.1M

Sector Composition

Rank Sector Weight
1 Healthcare 49.37%
2 Consumer Discretionary 6.42%
3 Industrials 5.53%
4 Financials 5.32%
5 Technology 5.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BGC
326
DELISTED
General Cable Corporation
BGC
$3.14M 0.05%
+182,100
New +$2.58M
VSI
327
DELISTED
Vitamin Shoppe Inc.
VSI
$3.12M 0.05%
75,675
+51,025
+207% +$2.16M
ED icon
328
Consolidated Edison
ED
$39.9B
$3.12M 0.05%
+51,087
New +$3.32M
SINA
329
DELISTED
Sina Corp
SINA
$3.11M 0.05%
96,763
-2,363
-2% -$84.9K
FAST icon
330
Fastenal
FAST
$56.7B
$3.09M 0.05%
+298,688
New +$3.23M
CNQ icon
331
Canadian Natural Resources
CNQ
$96.3B
$3.07M 0.05%
206,855
-107,076
-34% -$1.53M
GWW icon
332
W.W. Grainger
GWW
$61.8B
$3.05M 0.05%
+12,948
New +$3.09M
OPLN
333
Openlane
OPLN
$4.27B
$3.04M 0.04%
211,558
+62,951
+42% +$853K
BIOL
334
DELISTED
Biolase, Inc.
BIOL
$3.03M 0.04%
+120
New +$3.4M
AGI icon
335
Alamos Gold
AGI
$12.1B
$3.02M 0.04%
+515,982
New +$3.26M
KRE icon
336
State Street SPDR S&P Regional Banking ETF
KRE
$4.76B
$3.02M 0.04%
73,865
-27,754
-27% -$1.1M
DOOR
337
DELISTED
MASONITE INTERNATIONAL CORP
DOOR
$2.96M 0.04%
44,007
-26,888
-38% -$1.7M
DCOY
338
Decoy Therapeutics
DCOY
$2.18M
0
CADE
339
DELISTED
Cadence Bank
CADE
$2.93M 0.04%
126,376
-41,478
-25% -$904K
CCI icon
340
Crown Castle
CCI
$34B
$2.93M 0.04%
+35,500
New +$3.02M
NUE icon
341
Nucor
NUE
$62B
$2.92M 0.04%
61,453
+49,143
+399% +$2.3M
DNR
342
DELISTED
Denbury Resources, Inc.
DNR
$2.86M 0.04%
+392,608
New +$3.04M
CYBR
343
DELISTED
CyberArk
CYBR
$2.81M 0.04%
+50,500
New +$2.38M
BNFT
344
DELISTED
Benefitfocus, Inc.
BNFT
$2.78M 0.04%
75,537
-6,028
-7% -$180K
OMG
345
DELISTED
OM GROUP INC.
OMG
$2.76M 0.04%
+91,800
New +$2.67M
BMY icon
346
Bristol-Myers Squibb
BMY
$135B
$2.74M 0.04%
42,460
+38,360
+936% +$2.4M
EIX icon
347
Edison International
EIX
$27.7B
$2.73M 0.04%
43,701
-292,655
-87% -$19.1M
V icon
348
Visa
V
$692B
$2.69M 0.04%
+41,100
New +$2.72M
FRP
349
DELISTED
Fairpoint Communications, Inc.
FRP
$2.66M 0.04%
+151,100
New +$2.42M
XOM icon
350
ExxonMobil
XOM
$640B
$2.65M 0.04%
31,115
-32,415
-51% -$2.87M

Similar funds

Visium Asset Management's Q1 2015 Portfolio in Review

As of Q1 2015, Visium Asset Management held 1,363 positions worth $6.78B, down 4.3% from $7.08B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Visium Asset Management withdrew a net $1.04B in Q1 2015, closing 357 positions and reducing 313 holdings. Its most notable exit was Allergan Inc, an estimated $368M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 49% of assets, up from 47% a quarter earlier, followed by Consumer Discretionary and Industrials.

Against the trend, Visium Asset Management opened a new position in Akorn Inc worth $25.3M.

  • Visium Asset Management's largest Q1 2015 buy was Akorn Inc: 533,000 shares worth $25.3M.
  • Visium Asset Management added most to Perrigo in Q1 2015, an estimated $251M increase.
  • Visium Asset Management's biggest Q1 2015 reduction was Endo International plc, cutting an estimated $331M.
  • Visium Asset Management fully exited Allergan Inc in Q1 2015, selling an estimated $368M.
  • Visium Asset Management's ten largest holdings make up 29% of its $6.78B portfolio in Q1 2015.
  • Visium Asset Management opened 346 new positions and closed 357 in Q1 2015.
  • Visium Asset Management's portfolio value fell 4.3% quarter-over-quarter to $6.78B.

Based on Visium Asset Management's 13F filing for Q1 2015, filed 15 May 2015.